Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2004

View Archived Issues

Inhibition of beta-amyloid plaque formation by Cu/Zn chelating agent

Launch of Axid oral solution

New factor VIIa/TF inhibitors under study at Schering AG

Chinese researchers identify novel agents for renal disorders

Novel antitumor and antifungal compounds developed at Gemin X

New orexin-2 antagonists and their use in obesity and sleep disorders

New PTP-1B inhibitors described by Wyeth researchers

GSK researchers design novel thrombin/factor Xa inhibitors

Novel VEGFR inhibitors prepared and tested by ImClone researchers

Phase I results of spi-VEC vaccine for hepatitis B

Endovasc updates pipeline progress

FDA approval for Metvix

Maribavir enters phase II program in bone marrow transplant patients

Lexicon Genetics and Takeda team up on hypertension

Alimta receives positive endorsement from Advisory Committee for NSCLC

Approvable letter for Ionsys

Enanta and Shionogi enter agreement for EP-013420 in Japan and East Asia

Sunesis and Merck & Co. collaborate on discovery of novel antiviral drugs

EstroGel becomes first available transdermal estrogen gel in U.S.

Potent antiinflammatory and analgesic agent identified and tested at Orchid

Plantacor licenses preclinical cancer therapeutics from M. D. Anderson

Restructuring and R&D refocusing at Inflazyme

Completion of clinical portion of EXCEEDS phase IIIb study of Xyrem

PediaMed and Allergan enter pediatrics copromotion agreement for Tazorac

Neurokinin 1 receptor antagonist effective against postoperative fibrous adhesions

ChiRhoClin launches human secretin

Assessment of Bcl -2 family members as targets for antisense therapy in melanoma

Immunostimulatory effects of loxoribine in monocyte-derived DCs

Photodynamic therapy with Metvix shows efficacy in actinic cheilitis

MRI improvements found with a single dose of natalizumab in relapsing MS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...